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Globally, autism spectrum disorder (ASD) affects approximately 1 in 100 children.1 Ideally, a diagnosis is made with
the onset of symptoms before 3 years of age; however, a diagnosis may sometimes be delayed until 6 years or later.
There has been an increase in ASD research over the last few
decades, with many systematic reviews and meta-analyses
synthesizing research evidence for ASD interventions in
children. Evidence tends to support the notion that intervention for ASD must occur as early as possible, close to the
critical periods when early social and communication skills
are developing. Therefore, early screening and intervention
could improve the treatment outcomes of individuals with
autism, not only helping them survive but to thrive.2
Franz et al.3 have conducted an overview of reviews to
synthesize early intervention literature for very young children at risk for ASD with the aim of identifying which interventions have the strongest evidence base for impact.
Researchers, including Franz et al., acknowledge that while
many interventions impact child development, heterogeneity
in child outcome measures (behavioural coding and structured observation assessments), treatment and intervention
approaches, comparison groups, and participant profiles
limit the extent to which we can concretely evaluate the effectiveness of interventions. Robust high-quality evidence
is urgently needed to design international programmes that
can address the sometimes complex and varied needs of individuals with autism.
Moreover, there are also inadequacies regarding the regional coverage of studies on ASD. The primary studies in
these reviews were all from high-income settings (e.g. the USA
and UK). Not a single primary study in the review by Franz
et al.3 was identified from low-and middle-income countries
(LMICs). There is an urgent need to generate evidence on the
most appropriate intervention approaches for ASD in LMICs.
Even as we advocate for more research on early intervention
for children with ASD in LMICs, there is a need for further
testing of interventions that provide high impact at a relatively low cost, given the limited resources in these settings

and many competing priorities in overstretched health and
educational settings. It has been argued that interventions that
are community-based, empoweri caregivers and can be used
to address the needs of children with different developmental
delays may be the best options in these LMICs. In recent years
the World Health Organization and Autism Speaks have led in
the development and piloting of the Caregiver Skills Training
programme (an intervention that addresses communication
and behavioural problems across developmental conditions),
which has the potential to address this gap and be used at scale
in resource-constrained settings.4
In addition to the inclusion of applicable interventions in
LMIC settings, there is ongoing discussion on the balance of
benefits and harms of interventions in ASD research, with
the consensus being that there is a dearth in the reporting of
adverse events or observed harms.5 There is a need to address
this issue and the high risk of bias through the application of
fundamental standards in ASD intervention research.
In conclusion, Franz et al.3 have carried out a significant
piece of work in early ASD intervention research by providing an overview of systematic reviews and primary studies
therein. The authors call for a balance of research strategies
to bridge the community implementation gap in early ASD
intervention as there is a global disparity in who participates
and benefits from intervention research.
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Integrated biopsychosocial pain research in intellectual and
developmental disability
Historically, it was widely believed that individuals with
intellectual and developmental disability (IDD) were insensitive or indifferent to pain. Current consensus is that,
although cognitive impairment may affect the ability to understand and communicate pain, there is no conclusive evidence of altered pain experience. In most cases, individuals
with IDD show reliable, observable behaviors when they are
experiencing pain, and these behaviors can be used as pain
indicators by parents and clinical care staff.1 This shift in
perspective has led to the development of standardized tools
to measure pain in this population. Currently, best practice
is to use standardized observational pain scales, along with
other sources of information, whenever there is a suspicion
of pain in an individual with IDD. In this context, the work
of Sierra-Núñez et al. has important clinical implications for
pain assessment among children and adolescents with cerebral palsy (CP) in the post-surgical context and beyond.2
Their review suggests that the adapted FLACC (Face, Legs,
Activity, Cry, Consolability) scale3 is the tool that has been
the most widely used for postoperative pain assessment in
CP, and has the best reliability, validity, and feasibility evidence in clinical settings. Although further validation and
refinements efforts are always desirable, consistent use of the
FLACC or similarly well-validated scales is the best way to
reduce disparities in pain assessment and treatment among
individuals with IDD in the immediate future.
The review by Sierra-Núñez et al.,2 however, also shows
that there remains much work to be done. Their results indicate that, in most cases, individuals with CP and associated
intellectual disability were less likely to have their pain assessed, and received lower overall pain scores when they were
assessed, compared to their typically developing peers. The
specific reasons for these discrepancies are currently unclear,
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and further research is needed to investigate sources of variation in postoperative pain assessment in this population.
Effective pain assessment and treatment for individuals
with CP and other forms of IDD across the lifespan will require integrative, multidisciplinary care that takes into account the biological, social, and psychological determinants
of pain.4 As pointed out by Sierra-Núñez et al., input from
parents regarding how their children behave when they are in
pain can be an important source of information when individuals show idiosyncratic or unusual pain responses that may be
missed by unfamiliar observers. How parents' own pain histories and social and psychological factors influence their perceptions of their children's pain has received little attention
in the field of IDD. Our group recently documented that parents' self-reported pain catastrophizing, a psychological construct reflecting parents' thoughts and beliefs around their
child's pain, was related to change in both directly-observed
and parent-reported pain scores following a putatively pain
relieving procedure (i.e. intrathecal baclofen pump injection)
among children and adolescents with CP.5 The results were
complicated in that the relationship between pain catastrophizing and pain outcomes was moderated by the children's
language abilities, suggesting that the social nature of pain
expression and interpretation may be altered among children
with CP who cannot self-report. Further work in this area is
needed to understand how pain expression is shaped among
individuals with IDD to ensure that all individuals have equitable access to accurate pain assessment and treatment.
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